{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T15:40:01Z","timestamp":1745768401274,"version":"3.40.4"},"reference-count":17,"publisher":"BMJ","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Case Reports"],"abstract":"<jats:p>Targeting epidermal growth factor receptor (EGFR)-mediated signalling pathways has become routine practice in the treatment of lung cancer. Erlotinib is an oral EGFR tyrosine kinase inhibitor, licensed for maintenance monotherapy treatment in patients with locally advanced or metastatic non-small cell lung cancer after first-line chemotherapy. The authors present the case of a 51-year-old patient who had an excellent response to erlotinib, but developed unilateral onycholysis as an unusual side effect. The authors discuss erlotinib-induced skin and nail changes and have provided a brief literature review on the available evidence for their management.<\/jats:p>","DOI":"10.1136\/bcr.04.2011.4157","type":"journal-article","created":{"date-parts":[[2011,8,15]],"date-time":"2011-08-15T11:58:06Z","timestamp":1313409486000},"page":"bcr0420114157","source":"Crossref","is-referenced-by-count":1,"title":["Unilateral onycholysis in a patient taking erlotinib (Tarceva)"],"prefix":"10.1136","volume":"2011","clinical-trial-number":[{"clinical-trial-number":"nct00473083","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00531934","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00910676","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00531934","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Robert","family":"Stevenson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"El-Modir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2011,8,15]]},"reference":[{"key":"2025042707593176000_2011.aug11_1.bcr0420114157.1","unstructured":"Lacouture ME Melosky BL . Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: A Dermatology-Oncology perspective. Skin Therapy Lett 2005;12 http:\/\/www.skintherapyletter.com\/2007\/12.6\/1.html (accessed 15th January 2011)"},{"key":"2025042707593176000_2011.aug11_1.bcr0420114157.2","unstructured":"Tarceva product information website. http:\/\/www.tarceva.net\/portal\/eipf\/pb\/tarceva\/erlotinib\/home (accessed 15th January 2011)"},{"key":"2025042707593176000_2011.aug11_1.bcr0420114157.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050753"},{"key":"2025042707593176000_2011.aug11_1.bcr0420114157.4","unstructured":"Erlotinib for the treatment of non-small cell lung cancer. NICE technology appraisal guidance 162. http:\/\/www.nice.org.uk\/nicemedia\/live\/11777\/42657\/42657.pdf (accessed 15th January 2011)"},{"key":"2025042707593176000_2011.aug11_1.bcr0420114157.5","unstructured":"Tarceva approved EU product label. http:\/\/www.tarceva.net\/fmfiles\/re787003\/Product_Label\/emea-combined-h618en.pdf (accessed 15th January 2011)"},{"key":"2025042707593176000_2011.aug11_1.bcr0420114157.6","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1970"},{"key":"2025042707593176000_2011.aug11_1.bcr0420114157.7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi279"},{"key":"2025042707593176000_2011.aug11_1.bcr0420114157.8","unstructured":"Hecker MS Hecker D . Onycholysis. http:\/\/emedicine.medscape.com\/article\/1105738-overview (accessed 15th January 2011)"},{"key":"2025042707593176000_2011.aug11_1.bcr0420114157.9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1128\/CMR.11.3.415","article-title":"Onychomycosis: pathogenesis, diagnosis, and management","volume":"11","author":"Elewski","year":"1998","journal-title":"Clin Microbiol Rev"},{"key":"2025042707593176000_2011.aug11_1.bcr0420114157.10","unstructured":"Tosti A . Onychomycosis. http:\/\/emedicine.medscape.com\/article\/1105828-overview#a0104 (accessed June 28th 2011)"},{"key":"2025042707593176000_2011.aug11_1.bcr0420114157.11","doi-asserted-by":"crossref","first-page":"15622","DOI":"10.1200\/jco.2008.26.15_suppl.15622","article-title":"Survival benefit with erlotinib-based chemotherapy in unoperable recurrent and\/or metastatic pancreatic cancer","volume":"26","author":"Samelis","year":"2008","journal-title":"J Clin Oncol"},{"key":"2025042707593176000_2011.aug11_1.bcr0420114157.12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5070\/D31NF6W9Q1","article-title":"Unilateral taxane-induced onychopathy in a patient with a brain metastasis.","volume":"15","author":"Truchuelo","year":"2009","journal-title":"Dermatol Online J"},{"key":"2025042707593176000_2011.aug11_1.bcr0420114157.13","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-5-610"},{"key":"2025042707593176000_2011.aug11_1.bcr0420114157.14","first-page":"236","article-title":"The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors.","volume":"4","author":"Lacouture","year":"2006","journal-title":"J Support Oncol"},{"key":"2025042707593176000_2011.aug11_1.bcr0420114157.15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq387"},{"key":"2025042707593176000_2011.aug11_1.bcr0420114157.16","unstructured":"Dunne M Sumner D . EGFR inhibitors: Toxicities and Strategies for Effective management. http:\/\/www.medscape.org\/viewarticle\/579711 (accessed 5th february 2011)"},{"key":"2025042707593176000_2011.aug11_1.bcr0420114157.17","unstructured":"Clinical trials registry. http:\/\/clinicaltrials.gov\/ct2\/results?term=erlotinib+skin&pg=1 (accessed 5th february 2011)"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr.04.2011.4157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T14:59:42Z","timestamp":1745765982000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr.04.2011.4157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,15]]},"references-count":17,"alternative-id":["10.1136\/bcr.04.2011.4157"],"URL":"https:\/\/doi.org\/10.1136\/bcr.04.2011.4157","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2011,8,15]]}}}